Altimmune, Inc. · Drugmakers

ALT

High riskNext report: Around Nov 5 (est.)

View price ↗

The short version

A company still losing money with growing sales, with high risk. Institutions are adding.

Going well

Sales up 105% last year
Little debt

Watch out for

About 8 months of cash left at its current burn
Share count growing 23.4% a year (dilution)
Losing money, losses are large next to sales

Money moves

No insider buying or selling in the last 30 days
Institutions added 119% to their holdings in the quarter ending June 2026 (146 bought, 51 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$2.05-2.8% that day

Company value: $399M; Share price times all shares
Cash vs value: 16%; Cash as a share of company value
Debt vs value: 9%; Debt as a share of company value

From ALT's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

Not reported

Sep '23Tap a barJun '26

Over 5 years, sales shrank about 65% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of ALT. Starting points are the company's recent numbers (it isn't profitable yet, so the margin starts at a 10% guess).

Sales growth-10% a yearRecently: -65% a yearProfit margin10%Not reportedP/E at the end15xMany steady companies trade at 12x to 25xShare count change+10% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$0M

Profit in 5 years$0M

Price these guesses point to$0.00-100% vs $2.05 todayAbout -86% a year, before dividends

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

1/6Weak

MissReturn on equity 15%+Earns a lot on the money owners have in the business.-50.6%
PassDebt under half of equityNot relying on borrowed money.0.15x equity
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.Losses many times its sales
MissProfitable every yearSteady profits, not one good year.0 of 10 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$67.5M
MissShare count not growingNot diluting owners. Falling means buybacks.+87.7% in 3 years

Revenue: $41K; +105.0% vs prior year
5-year growth: -65.3%/yr; revenue, per year
Total debt: $34.3M; 0.15x equity
Current ratio: 18.55x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: gross margin 40%+. A checklist is a starting point for research, not a verdict.